{
  "nodes": [
    {
      "id": "node_001",
      "content": "Progression on osimertinib or amivantamab-vmjw + lazertinib",
      "parent_ids": [],
      "children_ids": [
        "node_002",
        "node_003"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "yy",
        "tt"
      ]
    },
    {
      "id": "node_002",
      "content": "Asymptomatic",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_004"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_003",
      "content": "Symptomatic",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_005",
        "node_006"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_004",
      "content": "\u2022 Consider definitive local therapy (eg, SABR or surgery) for limited lesions\n\u2022 Continue osimertinib or amivantamab-vmjw + lazertinib",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_012"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "o",
        "zz",
        "tt"
      ]
    },
    {
      "id": "node_005",
      "content": "Brain",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [
        "node_007"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_006",
      "content": "Systemic",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [
        "node_008",
        "node_009"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_007",
      "content": "\u2022 Consider definitive local therapy (eg, SRS)\n\u2022 Continue osimertinib or amivantamab-vmjw + lazertinib\n\u2022 NCCN Guidelines for CNS Cancers",
      "parent_ids": [
        "node_005"
      ],
      "children_ids": [
        "node_012"
      ],
      "tree_ids": [
        "NCCN Guidelines for CNS Cancers"
      ],
      "footnote_labels": [
        "bbb",
        "tt"
      ]
    },
    {
      "id": "node_008",
      "content": "Limited progression",
      "parent_ids": [
        "node_006"
      ],
      "children_ids": [
        "node_010"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "zz"
      ]
    },
    {
      "id": "node_009",
      "content": "Multiple lesions",
      "parent_ids": [
        "node_006"
      ],
      "children_ids": [
        "node_011"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "aaa"
      ]
    },
    {
      "id": "node_010",
      "content": "\u2022 Consider definitive local therapy (eg, SABR or surgery)\n\u2022 Continue osimertinib or amivantamab-vmjw + lazertinib\nor\n\u2022 Therapy for multiple lesions, below",
      "parent_ids": [
        "node_008"
      ],
      "children_ids": [],
      "tree_ids": [],
      "footnote_labels": [
        "o",
        "tt"
      ]
    },
    {
      "id": "node_011",
      "content": "Amivantamab-vmjw (if not previously given) + carboplatin + pemetrexed (nonsquamous) (category 1) (preferred)\nor\nSystemic therapy\nAdenocarcinoma (NSCL-K 1 of 5)\nor Squamous Cell Carcinoma (NSCL-K 2 of 5)",
      "parent_ids": [
        "node_009"
      ],
      "children_ids": [
        "node_013"
      ],
      "tree_ids": [
        "NSCL-K 1 of 5",
        "NSCL-K 2 of 5"
      ],
      "footnote_labels": [
        "ccc",
        "ddd",
        "eee"
      ]
    },
    {
      "id": "node_012",
      "content": "Progression, see therapy for multiple lesions below",
      "parent_ids": [
        "node_004",
        "node_007"
      ],
      "children_ids": [],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_013",
      "content": "Progression",
      "parent_ids": [
        "node_011"
      ],
      "children_ids": [
        "node_014"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_014",
      "content": "Systemic Therapy, Subsequent (NSCL-K 4 of 5)",
      "parent_ids": [
        "node_013"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-K 4 of 5"
      ],
      "footnote_labels": []
    }
  ],
  "tree_references": [
    {
      "from_tree": "NSCL-22",
      "to_tree": "NCCN Guidelines for CNS Cancers",
      "description": "Referenced for CNS disease management"
    },
    {
      "from_tree": "NSCL-22",
      "to_tree": "NSCL-K 1 of 5",
      "description": "Systemic therapy for Adenocarcinoma"
    },
    {
      "from_tree": "NSCL-22",
      "to_tree": "NSCL-K 2 of 5",
      "description": "Systemic therapy for Squamous Cell Carcinoma"
    },
    {
      "from_tree": "NSCL-22",
      "to_tree": "NSCL-K 4 of 5",
      "description": "Subsequent systemic therapy after progression"
    },
    {
      "from_tree": "NSCL-22",
      "to_tree": "NSCL-D",
      "description": "Principles of Image-Guided Thermal Ablation Therapy"
    },
    {
      "from_tree": "NSCL-22",
      "to_tree": "NSCL-H",
      "description": "Principles of Molecular and Biomarker Analysis"
    },
    {
      "from_tree": "NSCL-22",
      "to_tree": "NSCL-J",
      "description": "Molecular or Biomarker-Directed Therapy"
    },
    {
      "from_tree": "NSCL-22",
      "to_tree": "NCCN Guidelines for Small Cell Lung Cancer",
      "description": "Referenced in footnote aaa regarding SCLC transformation"
    }
  ],
  "footnotes": [
    {
      "label": "o",
      "content": "IGTA therapy (eg, cryotherapy, microwave, radiofrequency) may be an option for select patients. See Principles of Image-Guided Thermal Ablation Therapy (NSCL-D)."
    },
    {
      "label": "nn",
      "content": "Principles of Molecular and Biomarker Analysis (NSCL-H)."
    },
    {
      "label": "rr",
      "content": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J)."
    },
    {
      "label": "tt",
      "content": "Prophylactic anticoagulation is recommended at the time of initiation to prevent venous thromboembolic events."
    },
    {
      "label": "yy",
      "content": "Beware of flare phenomenon in subset of patients who discontinue tyrosine kinase inhibitor (TKI). If disease flare occurs, restart TKI."
    },
    {
      "label": "zz",
      "content": "Clinical trials have included up to 3 to 5 progressing sites."
    },
    {
      "label": "aaa",
      "content": "Consider a biopsy at time of progression to rule out small cell lung cancer (SCLC) transformation (approximately 6%) and biopsy or plasma testing to evaluate mechanisms of resistance. See Principles of Molecular and Biomarker Analysis (NSCL-H) and NCCN Guidelines for Small Cell Lung Cancer."
    },
    {
      "label": "bbb",
      "content": "Definitive local therapy of CNS disease can include asymptomatic lesions at risk for symptomatic progression based on factors including site, location, and edema."
    },
    {
      "label": "ccc",
      "content": "Not an option for EGFR S768I, L861Q, and/or G719X mutations."
    },
    {
      "label": "ddd",
      "content": "Afatinib + cetuximab may be considered in patients with disease progression on EGFR TKI therapy."
    },
    {
      "label": "eee",
      "content": "The data in the second-line setting suggest that programmed cell death protein 1 (PD-1)/PD-L1 inhibitor monotherapy is less effective, irrespective of PD-L1 expression, in EGFR exon 19 deletion or exon 21 L858R, ALK+ NSCLC."
    }
  ],
  "extraction_confidence": 0.95,
  "image_title": "EGFR EXON 19 DELETION OR EXON 21 L858R MUTATIONS - SUBSEQUENT THERAPY",
  "tree_id": "NSCL-22"
}